Lugano, Switzerland, 27 August 2025 – The Molecular Analysis for Precision Oncology Congress 2025 (MAP) will bring together leading experts to explore the latest advances in cancer research, with a focus on deepening the understanding of disease mechanism and enhancing strategies for prevention and interception. Key topics will include the integration of AI in diagnostics and therapy, alongside advances in immunotherapy and emerging developments in aging, cellular senescence, the microbiome, and cancer metabolism — all contributing to the evolving landscape of precision oncology.
The congress will be held onsite in Paris, France, from 15-16 September, with no virtual option available.
Programme picks
- Data on T cell behavior analyse changes in the immune system during cancer development, providing insights to intercept the disease at the pre-cancer stage before it progresses to a more advanced form.
- Related Content: Abstracts 178O, 22MO; educational session
- Findings on the use of spatial multi-omic mapping in certain breast cancer types to investigate factors influencing ctDNA release and the transition from early-stage to invasive disease.
- Insights into artificial intelligence in cancer research: from developing a computer model to detect early signs of cachexia in brain cancer patients, to creating AI-powered digital twins of tumors to improve treatment and outcomes in Cancer of Unknown Primary (CUP).
- Results from a trial exploring how low levels of genomic alterations are associated with exceptional and unexpected responses to targeted therapies in patients with advanced solid tumors.
- Related Content: Abstract 125O
-
Keynote Lecture “Cancer genomics and mutational processes” by Núria López-Bigas, 16 September 2025, 14:00 – 14:30 CEST
The abstracts will be published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
The MAP organisers welcome press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for MAP 2025. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditations will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
MAP Press Office
press@esmo.org
MAP is a joint initiative of Cancer Research UK (CRUK), Unicancer and the European Society for Medical Oncology (ESMO).
Notes to Editors
Please make sure to use the official name of the meeting in your reports: MAP 2025 and the official congress hashtag #MAP2025. Follow it to stay up to date and use it to take part in the conversation on X, LinkedIn, Bluesky, Instagram, Facebook, YouTube.
About the European Society for Medical Oncology (ESMO)
Representing more than 40,000 oncology professionals from 179 countries and territories, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org
About Cancer Research UK (CRUK)
Cancer Research UK is the world’s leading cancer charity, dedicated to saving and improving lives with our research, influence and information. We carry out world-class research into the prevention, detection and treatment of more than 200 types of cancer through the work of more than 4,000 scientists, doctors and nurses. We make discoveries about cancer that unlock new and better ways to beat it, and we translate these discoveries into new tests, treatments and prevention measures that can save and improve lives in the UK and around the world. Our vision is a world where everybody lives longer, better lives, free from the fear of cancer. Step by step, day by day, our researchers are making this vision a reality thanks to our dedicated community of supporters, partners, donors, fundraisers, volunteers and staff.
Unicancer is the only French hospital network that is 100% dedicated to the fight against cancer and the only national hospital federation that specializes in cancer. It brings together the 18 French Cancer Control Centers (CLCC) – private non-profit institutions – as well as two affiliated members. A major player in research, Unicancer is the leading academic promoter of clinical trials in oncology in Europe, with more than 120 active studies (national and international), including 50 currently recruiting, promoted by its R&D department. In addition, there are more than 600 trials promoted by the CLCCs. A pioneer in the use of health data, Unicancer has launched since 2014, via its data and partnerships department, five real-life data programs, including ESME (109,000 patients), CANTO (+13,000 patients), and OncoDataHub (ODH) (+60,000 patients). Each year, more than 600,000 patients benefit from the latest scientific, therapeutic, and organizational advances in cancer, driven by an agile model combining excellence, humanism, solidarity, and innovation. www.unicancer.fr